Navigation Links
EntreMed Reports Third Quarter 2008 Financial Results
Date:11/6/2008

tiated in 2006 and 2007. We expect research and development expenses to trend down in the fourth quarter and into 2009 as we collect clinical data and evaluate each program to determine future clinical direction. At the end of the quarter we reported $27.9 million in cash and short-term investments, which together with anticipated royalty inflows, we believe will fund planned operations for at least the next 12 months."

James S. Burns, EntreMed President and Chief Executive Officer, commented, "We are actively pursuing partners for ENMD-2076 and Panzem(R) RA while continuing our clinical oncology programs, including the Phase 1b dose-escalation study in solid tumors for ENMD-2076. The outcome of our partnering initiatives and anticipated clinical progress will guide our priorities through year-end and into 2009. While we are reducing overall expenses, our clinical trials remain on schedule. We anticipate the presentation of clinical and preclinical data for MKC-1, ENMD-2076 and ENMD-1198 over the next several quarters."

Mr. Burns will present a Company overview at the Rodman & Renshaw 10th Annual Healthcare Conference, which will serve as the Company's third quarter 2008 update. Mr. Burns' presentation is scheduled for 2:25 p.m. (ET) on Tuesday, November 11, 2008 and will be web cast. To access the live presentation, visit the Company's web site at http://www.entremed.com. An archive of the presentation will be available on the web site for approximately 90 days.

About EntreMed

EntreMed, Inc. is a clinical-stage pharmaceutical company developing therapeutic candidates primarily for the treatment of cancer and inflammation. MKC-1, an oral cell-cycle regulator with activity against the mTOR pathway, is currently in multiple Phase 2 clinical trials for cancer. ENMD-2076, a selective angiogenic kinase inhibitor, and ENMD-1198, a novel antimitotic agent are in Phase 1 studies in advanced canc
'/>"/>

SOURCE EntreMed, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. EntreMeds ENMD-2076 Demonstrates Tumor Regression in Human Colon Cancer Model
2. EntreMed to Present at BioPartnering Europe Conference
3. EntreMed Announces Stock Listing Transfer to Nasdaq Capital Market
4. EntreMed Reports Second Quarter 2008 Financial Results
5. EntreMed Appoints Thomas H. Bliss as Senior Vice President of Corporate and Business Development
6. Dana-Farber Cancer Institute Commences Phase 1 Trial With EntreMeds Selective Kinase Inhibitor
7. EntreMed Will Not Seek Shareholder Approval for Reverse Stock Split at Annual Meeting
8. EntreMeds Kinase Inhibitor, ENMD-2076, Presented During AACR Special Session
9. EntreMed Receives Nasdaq Deficiency Notice
10. EntreMed to Present at BioCentury Future Leaders in the Biotech Industry Conference
11. EntreMed Announces 2008 Corporate and Clinical Program Priorities
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... November 21, 2014 2014 Deep ... professional and in-depth research report on the transformer ... definition, classification, application, and industry chain structure as ... international market analysis, including China’s domestic market as ... & economic situation analysis. The report also covers ...
(Date:11/21/2014)... /CNW/ - Aequus Pharmaceuticals Inc. (the "Company" or ... closed a brokered private placement offering (the "Brokered ... Cormark Securities Inc. and Clarus Securities Inc. acted ... a syndicate of agents that also included Wolverton ... "Agents"). Concurrently with the Brokered Offering, the Company ...
(Date:11/21/2014)... , Nov. 20, 2014 /PRNewswire/ - BIOREM Inc. (TSXV: BRM) ("Biorem" ... nine month periods ended September 30, 2014.  Biorem,s complete 2014 third ... www.sedar.com ). Financial Summary:Three-months ended September 30, ... per share data) , 2014 , 2013 ... 2,282 , 5,281 , 6,715 , ...
(Date:11/18/2014)... 17, 2014 RPS Diagnostics (RPS®) ... – today announces its third annual partnership of ... Get Smart About Antibiotics Week from November 17-23. ... national campaign designed to highlight the coordinated efforts ... non-profit and for-profit partners to provide education about ...
Breaking Biology Technology:International Transformer Industry - Analysis on Applications, Development & Forecasts Now Available at ReportsnReports.com 2International Transformer Industry - Analysis on Applications, Development & Forecasts Now Available at ReportsnReports.com 3Aequus Pharmaceuticals closes $4.2 million private placement financing 2Aequus Pharmaceuticals closes $4.2 million private placement financing 3Biorem Reports Third Quarter Results 2Biorem Reports Third Quarter Results 3RPS Again Partners with the CDC in Support of the 2014 Get Smart About Antibiotics Week 2RPS Again Partners with the CDC in Support of the 2014 Get Smart About Antibiotics Week 3
... BEIJING, June 2 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (NYSE ... of vaccines in China, announced today that,China,s Vice Premier, ... State Council, Ma Kai; Head of General Administration of,Quality ... Health, Chen Zhu; Vice Minister of Ministry of Science ...
... , NEW YORK, June 2 Delcath Systems, Inc. ... testing its proprietary treatment method for primary and metastatic ... States Food and Drug Administration ("FDA") granted Delcath,s application ... treatment of patients with neuroendocrine tumors. , , ...
... MOUNTAIN VIEW, Calif., June 2 VIVUS, Inc. (Nasdaq: ... next-generation therapies to address unmet needs in obesity, diabetes ... be featured in two podium presentations during the 69th ... held from June 5-9, 2009 in New Orleans, Louisiana. ...
Cached Biology Technology:China's Vice Premier, Li Keqiang, Visits Sinovac to Inspect H1N1 Vaccine Production Preparation 2China's Vice Premier, Li Keqiang, Visits Sinovac to Inspect H1N1 Vaccine Production Preparation 3Delcath Systems Granted Third Orphan Drug Designation 2Delcath Systems Granted Third Orphan Drug Designation 3Data on VIVUS' Qnexa To Be Presented During Two Podium Presentations at ADA Annual Meeting 2Data on VIVUS' Qnexa To Be Presented During Two Podium Presentations at ADA Annual Meeting 3
(Date:11/4/2014)... amount of death at the right time might actually ... research that could help in understanding animal populations, pest ... a paper in the journal Trends in Ecology ... colleagues conclude that the kind of positive population effect ... or mortality, depends on the size and developmental stage ...
(Date:11/4/2014)... 2014   3D ... Fuel3D , a developer of 3D scanning ... totaling $6.4 million (£4 million). This funding builds on the ... year and paves the way for the commercial launch of ... funding round was led by Chimera Partners and will be ...
(Date:11/3/2014)... published in this month,s Proceedings of the ... a recently discovered communication molecule of the body,s immune ... to limit inflammation and the current study reports its ... ability of the immune system to recognize and target ... effect on the immune system now allows us to ...
Breaking Biology News(10 mins):When less is more: Death in moderation boosts population density in nature 2Fuel3D Secures $6.4 Million in Expansion Funding 2Fuel3D Secures $6.4 Million in Expansion Funding 3PNAS: From HIV to cancer, IL-37 regulates immune system 2
... -- Microbes living at the bottom of the Gulf of ... the Deepwater Horizon oil spill than previously thought, according to ... A paper on that research, conducted before the Deepwater ... a forthcoming issue of the journal Deep-Sea Research II ...
... cells live ever on the verge of suicide, requiring ... prevent the cells from pulling the trigger. This self-destructive ... dangerous precancerous cells are permitted to kill themselves, but ... that store memories, for instance. Rockefeller University scientists are ...
... [Brown University] Living with HIV is difficult under ... virus, alcohol consumption can become particularly perilous in intricate ... the Brown Alcohol Research Center on HIV (ARCH) funded ... Institutes of Health, Brown University scientists will study the ...
Cached Biology News:Microbes may consume far more oil-spill waste than earlier thought 2'Reaper' protein strikes at mitochondria to kill cells 2$7.5M grant to fund research on interaction of drinking and HIV infection 2$7.5M grant to fund research on interaction of drinking and HIV infection 3
Collected from animals that are 16 to 18 months old. Sterile, Cell culture tested, ID clarifier: USA Origin...
... a cytochrome P450 (CYP450) metabolite postulated to ... and cerebral vasculature. In rat cerebral microvessels, ... autoregulatory vasoconstriction. 20-HETE is excreted mainly as ... 20-HETE (20-40 pg/ml in human urine) is ...
... enables you to insert a transposable element ... by in vitro transposition. It uses TnsABC* ... the DNA target. Target DNA may be ... depending on your interests (6-8). If the ...
A set of five peptides which can be used to calibrate a Matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) or Electrospray Ionization (ESI) mass spectrometer....
Biology Products: